CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
BioPorto Diagnostics and QIAGEN have successfully validated the use of BioPorto’s gRAD lateral flow platform on QIAGENS’s ESEQuant LR3 Lateral Flow System.
By combining gRAD with the ESEQuant LRS system, this platform, provides a powerful and versatile toolbox for rapid development of lateral flow-based assays. This toolbox is well suited in the constantly shifting lateral flow market space, where the demand for new applications in human diagnostics, veterinary diagnostics, food industry and environmental/agriculture testing is rapidly increasing.
Jan Kuhlmann Andersen, COO of BioPorto, commented: “With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development. Through the combination of gRAD and the ESEQuant LRS system, BioPorto now has a complete assay development process in place to test across above mentioned business segments.”
Read more about the gRAD lateral flow technology and the ESEQuant LR3 Lateral Flow technology.
www.bioporto.com/Products/Product-by-category/Lateral-flow.aspx
http://www.lateralflowreader.com/new-powerful-option-esequant-lr3-grad/
For further information, please contact:
Peter Mørch Eriksen, CEO
Gry Husby Larsen, General Counsel
Telephone +45 4529 0000, e-mail [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3275dac8-8136-4c84-a74d-b229acccc5eb
